Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. - Wikidata - wikimedia - TriplyDB

Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.

Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.

http://www.wikidata.org/entity/Q39212474

about

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma c-Met as a Target for Personalized Therapy Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.Four individually druggable MET hotspots mediate HGF-driven tumor progression.Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.The evolving landscape of glioblastoma stem cells.Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma.Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound.Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.Bevacizumab for glioblastoma: current indications, surgical implications, and future directions Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression.MET/HGF pathway activation as a paradigm of resistance to targeted therapies.GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer Targeting angiogenesis in renal cell carcinoma.Current status of antiangiogenic therapies for glioblastomas.Resistance to antiangiogenic therapy.Resistance to antiangiogenic therapies.Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies.Tivantinib: critical review with a focus on hepatocellular carcinoma.Antiangiogenic therapies for glioblastoma.Bevacizumab in high-grade gliomas: past, present, and future.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Tivantinib (ARQ197) in hepatocellular carcinoma.Recent advances in targeted therapy for glioblastoma.Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature.Glioblastoma targeted therapy: updated approaches from recent biological insights.Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy.

P2860

Q24564890-834E77C8-7520-4B53-A7C9-2A91DA365A3D Q26775483-32A2B3CD-96A2-441A-BC65-0694BE770254 Q27025007-39B41211-2550-46EF-B1F3-7131F085ABA2 Q30278053-AE24FECA-311F-4F08-85FD-4EFBFEF22043 Q30581656-C01D278D-3CCC-42B4-B98D-FE387DE26C9C Q33624367-AD17227E-1B39-47E2-B883-F3DC653FFDD2 Q33652614-FDC0C771-BB0B-479C-AC19-9657BD63DCDB Q33853991-6FFDFBFC-BD2C-4849-8046-0EE6AD61E5E1 Q33888739-717AA5C3-AB07-439A-B86A-D746A4B0BC12 Q34227712-1E6155A9-86FB-463B-BB3F-0A77F47510B6 Q34293163-B2DF2A7B-2D6D-4E51-90FE-6065A07AA6BA Q34807753-14C630AE-B008-4383-A91E-7F8B07946E16 Q34964958-9E06BE15-6061-4193-AE4E-989488764F2D Q34978329-E838BBC2-5864-47DF-9A97-350DFA4AAAB6 Q35987408-1B2F28FF-7C79-4D61-9EDD-5DDC0B8760D3 Q36229899-D9D67795-DB66-433A-BFF0-5130A948C776 Q36413742-1BFB356D-7C55-4EDC-B248-9A8B6525FAE5 Q36822207-C1B57150-9FD2-4313-A4D1-5F0447D2C94E Q37014134-8E8B7733-D0BF-4BAC-94B0-ED204CC91B7C Q37153834-04B7B59C-8D3B-4B9D-AC6E-D411F0A97019 Q37218231-12D8ED3B-CD34-4FED-895C-C0A4F9E1A933 Q37597850-F6050696-3D1B-49F2-97C3-C1B91F7DECBB Q37599547-91A783E4-09F8-4AA5-B346-6D7865D02FDC Q37687269-E1ADFD6A-3429-4DA9-A719-4E2F7474CD7A Q37702041-513D894C-597A-49AC-8EF4-E6D397F027AD Q38125964-AC03A1DE-616E-47F5-BCEC-9CAC49565347 Q38132231-0931B18B-A0AE-4ED5-ACC6-90155459CD97 Q38169761-30CEBCBC-F49B-42F7-8744-010B1542D5E9 Q38197943-93028C31-0DE1-4229-8EDE-2DA652557F4B Q38232852-91484DC4-2CAE-4EC2-985E-A3EBFED9C9A1 Q38238607-660F212A-9E8D-4DA0-902F-6F98F368565A Q38259343-463C28C5-2603-439C-8CDA-B6F028406CA2 Q38264310-25E9254C-99AE-47C4-B5CC-F47387B5F206 Q38386873-1C45DFD0-4E83-4585-9233-5F44C4D6ED19 Q38498207-6BE234C0-6950-478B-AEDA-54401EDEAD35 Q38513062-3533D2C9-6171-4159-AA9A-D102D1556629 Q38539386-DB8CB450-8059-4008-A102-5FCF2E550DDC Q38554801-F5BF65E7-FFD5-4D7B-B500-0268456462E6 Q38597700-AB729940-8751-4D38-971A-2248AE8CC5F2 Q38599484-C8A74A59-2724-40B7-A0E8-D5693AFCF30F

P2860

Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.

http://www.wikidata.org/entity/Q39212474

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Gene expression profile identi ...... angiogenic therapy resistance.

@en

Gene expression profile identi ...... angiogenic therapy resistance.

@nl

type

label

Gene expression profile identi ...... angiogenic therapy resistance.

@en

Gene expression profile identi ...... angiogenic therapy resistance.

@nl

prefLabel

Gene expression profile identi ...... angiogenic therapy resistance.

@en

Gene expression profile identi ...... angiogenic therapy resistance.

@nl

P1433

Q39212474-CB328AAC-7F67-48E5-B341-C027F3411FE5

P1476

Q39212474-981F199E-B770-4674-A840-D242243825EE

P2093

Q39212474-0319573D-6B28-4305-8122-73FC2F15CF84

Q39212474-074C3E60-E494-4178-BDE7-AF5F216A5040

Q39212474-115A5A37-0744-4888-BB6C-7AEAFA360668

Q39212474-226D3BE6-67BD-4284-9774-885DF8E86300

Q39212474-494F58DC-EA97-4ECB-9530-9EE1FCEC45FB

Q39212474-5CC8746B-87CF-4C6F-A0EC-0CB2C4D8C009

Q39212474-751DFF68-9110-499A-AD7C-0AEE3A42ABB0

Q39212474-76EB6DF7-BEED-4A00-B927-745E447EDB74

Q39212474-8BAFE649-0E6C-4C0E-ABC1-002D2EB51409

Q39212474-92F6AECA-842A-470A-8DA8-E07907EEEE12

P2860

Q39212474-002D6048-6172-41BD-BAC7-C31C216D4474

Q39212474-0508680E-EABC-45FB-B289-B9D766A317A0

Q39212474-058DC484-4B09-46A8-A476-87EE2BE9F9B1

Q39212474-0A44DFE1-A03E-456C-934B-D25E77F396B9

Q39212474-0CD36FB5-2F57-429E-BE96-9077BA1601B8

Q39212474-136D3885-D0DB-4DF4-A435-F2346AA86D80

Q39212474-1462C829-4B6D-4C01-AE15-3746066A5FED

Q39212474-167A3E63-154B-47B3-8AB5-BE09785DC0DB

Q39212474-17B97477-94FF-47DE-BCC6-8C10F176CE87

Q39212474-18F7AAA7-F288-43AC-9CDA-BE73D563079B

P304

Q39212474-EFC26802-EF5A-4026-A839-71618A0ECE46

P31

Q39212474-DA22C1B9-0744-424B-9C26-CA2079AE1DC9

P356

Q39212474-2DDEF4F4-4B31-47BC-BECB-E7E8E0103D63

P407

Q39212474-BFAC7A1B-DD15-4429-9C9D-80E6054135A3

P433

Q39212474-DA5CEC41-44B6-4476-ABD1-90C9ECE7A72B

P478

Q39212474-5C43F4CC-C29D-49A1-AB6C-DF1AECAB99D5

P50

Q39212474-01B9F2C7-D8AE-47CE-92D9-D545E116DF61

P577

Q39212474-E80F9760-1B0A-41DD-A7C2-48AFCDAFFB7B

P698

Q39212474-1E168928-DE9A-4038-9919-E95A8B5D3756

P932

Q39212474-AB7D4121-5265-4DA3-B9DE-4348357F793D

P356

1078-0432.CCR-12-1281

P1433

Clinical Cancer Research

P1476

Gene expression profile identi ...... angiogenic therapy resistance.

@en

P2093

Arman Jahangiri

http://www.w3.org/2001/XMLSchema#string

Gabriele Bergers

http://www.w3.org/2001/XMLSchema#string

Jesse Paquette

http://www.w3.org/2001/XMLSchema#string

Kan Lu

http://www.w3.org/2001/XMLSchema#string

Kirsten M Bjorgan

http://www.w3.org/2001/XMLSchema#string

Liane M Miller

http://www.w3.org/2001/XMLSchema#string

Manish K Aghi

http://www.w3.org/2001/XMLSchema#string

Maxwell W Tom

http://www.w3.org/2001/XMLSchema#string

Michael De Lay

http://www.w3.org/2001/XMLSchema#string

Myriam M Chaumeil

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

Modes of resistance to anti-angiogenic therapy

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Induction of epithelial tubules by growth factor HGF depends on the STAT pathway

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

Opposing roles of ERK and p38 MAP kinases in FGF2-induced astroglial process extension.

Activation and inhibition of mast cells degranulation affect their morphometric parameters.

Fundamentals of cDNA microarray data analysis.

Selection of differentially expressed genes in microarray data analysis.

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

P304

1773-1783

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-1281

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23307858

http://www.w3.org/2001/XMLSchema#string

P932

3618605

http://www.w3.org/2001/XMLSchema#string